Exelixis Inc. Stock
€35.27
Your prediction
Financial data and news for Exelixis
sharewise wants to provide you with the best news and tools for Exelixis, so we directly link to the best financial data sources.
Financials
News
Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is
Exelixis Q2 Revenue Falls 11 Percent
Exelixis (NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45